课题基金 / 基金详情

SARS-CoV-2 correlates of protection in a Latino-origin population

SARS-CoV-2 correlates of protection in a Latino-origin population
SARS-CoV-2 与拉丁裔人群的保护相关
批准号:
10706728
负责人:
Marcos Lopez
金额:
$40.71万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-09-30 至 2025-08-31
关键词:
2019-nCoVAfricanAmericanAntibodiesAntibody titer measurementAutoimmune DiseasesAutomobile DrivingBasic ScienceBiological AssayBlack AmericanBlack raceBlood CirculationCOVID-19COVID-19 severityCOVID-19 susceptibilityCOVID-19 testCOVID-19 vaccineClinicalCollaborationsCommunicable DiseasesDataDengueDetectionDevelopmentDisease OutcomeDissectionEnzyme-Linked Immunosorbent AssayEpidemiologyEtiologyFDA Emergency Use AuthorizationFutureGeneticGoalsHealth PolicyHealthcare SystemsHispanic PopulationsImmuneImmune responseImmunoglobulin AImmunoglobulin GImmunoglobulin MImmunologicsImmunophenotypingImmunosuppressionIndividualInfluenzaInstitutional Review BoardsIntegration Host FactorsIslandKnowledgeLaboratoriesLatin AmericanLatinoLatino PopulationLeadMalignant NeoplasmsMethodsModelingMolecularMycoplasmaObesityOutcomePatientsPatternPharmaceutical PreparationsPhenotypePlayPopulationPredispositionPrevalencePrivatizationPrognosisProtocols documentationPublic HealthPuerto RicanPuerto RicoResearchResearch PersonnelRespiratory syncytial virusRiskRoleSARS-CoV-2 antibodySARS-CoV-2 infectionSamplingScienceSerodiagnosesSerologySerology testSeroprevalencesSeveritiesSocial EnvironmentSourceSpeechT-LymphocyteTechnologyTestingTimeTrustUncertaintyVaccinesVirusVulnerable PopulationsWashingtonWorld Health OrganizationZIKAbiobankchikungunyaclinical diagnosticscohortcomorbiditycytokinediagnostic platformfollow-upinterestmedically underservedmemberneutralizing antibodynewsnovel coronaviruspandemic diseasepathogenprogramsracial disparityrecruitrepositorysevere COVID-19social groupsocial vulnerabilitysocioeconomicsstudy populationtransmission processvaccine candidatevolunteer

项目摘要

项目成果

Marcos Lopez的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The rapid global spread of SARS-CoV-2 has had a significant impact on the cancer population. SARSCoV-2 infection of hematopoietic stem cell transplant (HSCT) recipients leads to a poor prognosis with a ~68% survival rate. Immune mediated protection is critical to protect the HSCT population. However, there are significant gaps in our understanding of vaccine induced immune responses in the HSCT patient population. This proposed research will greatly advance our understanding of 1) mRNA vaccine driven immune responses in immune compromised subject populations, and 2) the functionality of the SARS-CoV-2 antigen specific T and B cell response in the HSCT population; 3) the role of the adaptive immune response in controlling breakthrough infections. The results of this proposal will have both short and long-term impacts. In the short term we will define a series of critical parameters that could improve the quality of life of HSCT patients during the pandemic. These studies will define the immunogenicity of mRNA SARS-CoV-2 vaccines before and after boosters. In two cohorts we will surveil for asymptomatic and symptomatic SARS-CoV-2 infections and evaluate the level of vaccine immunity close to the time of the breakthrough infection. In the long-term the SARS-CoV-2 pandemic was the 3rd global transmission of a novel coronavirus in the past 20 years. It is likely that there will be outbreaks in the future with currently unknown coronaviruses, and thus it is critical to determine now how high-risk groups respond to vaccination and if they require frequent booster vaccinations or potentially higher vaccine doses. Given the speed and efficacy of the mRNA vaccine platform, it is highly likely that the use of this vaccine platform will be expanded to combat other known pathogens, but also could be used to combat any range of potential emerging viral pathogens. The strength, breadth, and durability of responses to mRNA vaccines needs to be determined in different risk groups in longitudinal cohorts now, in order to prepare for future epidemics/pandemics.
期刊论文(5)
专著(0)
科研奖励(0)
会议论文
DOI: 10.3390/v13101972
发表时间: 2021-09-30
期刊: Viruses
影响因子: --
作者: [Sariol CAA, Pantoja P, Serrano-Collazo C, Rosa-Arocho T, Armina-Rodríguez A, Cruz L, Stone ETT, Arana T, Climent C, Latoni G, Atehortua D, Pabon-Carrero C, Pinto AKK, Brien JDD, Espino AMM]
通讯作者: Espino AMM
DOI: 10.1101/2021.10.25.21265422
发表时间: 2021
期刊: medRxiv : the preprint server for health sciences
影响因子: --
作者: [Sariol,CarlosA, Serrano-Collazo,Crisanta, Ortiz,EdwinJ, Pantoja,Petraleigh, Cruz,Lorna, Arana,Teresa, Atehortua,Dianne, Pabon-Carrero,Christina, Espino,AnaM]
通讯作者: Espino,AnaM
Function is more reliable than quantity to follow up the humoral response to the Receptor Binding Domain of SARS- CoV-2 Spike protein after natural infection or COVID-19 vaccination.
在追踪自然感染或 COVID-19 疫苗接种后对 SARS-CoV-2 刺突蛋白受体结合域的体液反应时,功能比数量更可靠。
DOI: 10.1101/2021.06.02.21257975
发表时间: 2021
期刊: medRxiv : the preprint server for health sciences
影响因子: --
作者: [Sariol,CarlosA, Pantoja,Petraleigh, Serrano-Collazo,Crisanta, Rosa-Arocho,Tiffany, Armina,Albersy, Cruz,Lorna, Stone,ETaylor, Arana,Teresa, Climent,Consuelo, Latoni,Gerardo, Atehortua,Dianne, Pabon-Carrero,Christina, Pinto,AmeliaK, Brien,]
通讯作者: Brien,
DOI: 10.3390/vaccines9080881
发表时间: 2021-08-09
期刊: Vaccines
影响因子: 7.8
作者: [King RG, Silva-Sanchez A, Peel JN, Botta D, Dickson AM, Pinto AK, Meza-Perez S, Allie SR, Schultz MD, Liu M, Bradley JE, Qiu S, Yang G, Zhou F, Zumaquero E, Simpler TS, Mousseau B, Killian JT Jr, Dean B, Shang Q, Tipper JL, Risley CA, Harrod KS, Feng T, Lee Y, Shiberu B, Krishnan V, Peguillet I, Zhang J, Green TJ, Randall TD, Suschak JJ, Georges B, Brien JD, Lund FE, Roberts MS]
通讯作者: Roberts MS
SARS-CoV-2 correlates of protection in a Latino-origin population
海外基金